The efficacy and safety of the antiplatelet therapy in acute non-cardiogenic ischemic stroke.
Phase 4
- Conditions
- on-cardiogenic ischemic stroke in acute phase.
- Registration Number
- JPRN-UMIN000006931
- Lead Sponsor
- Department of Neurosurgery, Faculty of Medicine, University of Tsukuba
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
Not provided
Exclusion Criteria
1) Having aphasia or mental retardation. 2) Having serious liver dysfunction, renal dysfunction, angina, myocardial infarction. 3) Having hemorrhagic disease. 4) Having tachyarrhythmia to need treatment. 5) A patient with suspected cardiogenic cerebral infarction. 6) Contraindication for cilostazol, aspirin, ozagrel, and edaravon.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The percentage of patients with mRS 0 to 3 at 3 months.
- Secondary Outcome Measures
Name Time Method 1) The frequency of progressive stroke on day 2 and7. 2) The frequency of stroke and myocardial infarction. 3) The frequency of hemorrhagic event. 4) The frequency of adverse event.